MCK vs. HOLX, HQY, HSIC, MMSI, AMN, CRL, HUM, ITGR, WST, and COR
Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Hologic (HOLX), HealthEquity (HQY), Henry Schein (HSIC), Merit Medical Systems (MMSI), AMN Healthcare Services (AMN), Charles River Laboratories International (CRL), Humana (HUM), Integer (ITGR), West Pharmaceutical Services (WST), and Cencora (COR). These companies are all part of the "medical" sector.
McKesson vs. Its Competitors
Hologic (NASDAQ:HOLX) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.
McKesson has higher revenue and earnings than Hologic. Hologic is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.
In the previous week, McKesson had 22 more articles in the media than Hologic. MarketBeat recorded 36 mentions for McKesson and 14 mentions for Hologic. McKesson's average media sentiment score of 1.07 beat Hologic's score of 0.76 indicating that McKesson is being referred to more favorably in the news media.
Hologic has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
Hologic presently has a consensus target price of $79.38, indicating a potential upside of 16.05%. McKesson has a consensus target price of $829.08, indicating a potential upside of 11.32%. Given Hologic's higher possible upside, equities research analysts plainly believe Hologic is more favorable than McKesson.
94.7% of Hologic shares are owned by institutional investors. Comparatively, 85.1% of McKesson shares are owned by institutional investors. 1.9% of Hologic shares are owned by insiders. Comparatively, 0.1% of McKesson shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Hologic has a net margin of 13.79% compared to McKesson's net margin of 0.84%. Hologic's return on equity of 19.69% beat McKesson's return on equity.
Summary
Hologic and McKesson tied by winning 8 of the 16 factors compared between the two stocks.
Get McKesson News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MCK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
McKesson Competitors List
Related Companies and Tools
This page (NYSE:MCK) was last updated on 10/3/2025 by MarketBeat.com Staff
Free MCK Stock Alerts